Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia

Blood. 2014 Dec 18;124(26):3932-8. doi: 10.1182/blood-2014-08-595389. Epub 2014 Oct 27.

Abstract

Obesity is associated with poorer event-free survival (EFS) in pediatric acute lymphoblastic leukemia (ALL). Persistent minimal residual disease (MRD) in the bone marrow as measured by multidimensional flow cytometry (MDF) is a key early prognostic indicator and is strongly associated with EFS. We therefore hypothesized that obesity during induction would be associated with positive end-of-induction MRD (≥0.01%). We analyzed MDF of end-induction bone marrow samples from a historical cohort of 198 children newly diagnosed with B-precursor ALL (BP-ALL) and treated with Children's Oncology Group induction regimens. We assessed the influence of body mass index on risk for positive end-induction MRD in the bone marrow. In our cohort of BP-ALL, 30 children (15.2%) were overweight and 41 (20.7%) were obese at diagnosis. Independent of established predictors of treatment response, obesity during induction was associated with significantly greater risk for persistent MRD (odds ratio, 2.57; 95% confidence interval, 1.19 to 5.54; P = .016). Obesity and overweight were associated with poorer EFS irrespective of end-induction MRD (P = .012). Obese children with newly diagnosed BP-ALL are at increased risk for positive end-induction MRD and poorer EFS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Body Mass Index
  • Body Weight
  • Bone Marrow / pathology
  • Child
  • Child, Preschool
  • Cohort Studies
  • Disease-Free Survival
  • Female
  • Flow Cytometry
  • Humans
  • In Situ Hybridization, Fluorescence
  • Infant
  • Leukemia / complications*
  • Leukemia / mortality
  • Male
  • Neoplasm, Residual / diagnosis
  • Obesity / complications*
  • Overweight
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy*
  • Prognosis
  • Proportional Hazards Models